A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension
Introduction: A Fixed-Dose Combination (FDC) of antihypertensive agents of different groups might offer advantages of efficacy, tolerability and compliance over monotherapy. Aim: To compare efficacy and tolerability of ramipril/torsemide FDC with ramipril monotherapy. Materials and Methods: Thi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2017-11-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/10819/24715_150917_24715_CE[Ra]_F(Sh)_PF1(AA_GG)_PFA(NC_MJ_SS).pdf |
id |
doaj-0a7ee71889804ffbbfa2278fa754c597 |
---|---|
record_format |
Article |
spelling |
doaj-0a7ee71889804ffbbfa2278fa754c5972020-11-25T03:26:39ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2017-11-011111OC05OC0910.7860/JCDR/2017/24715.10819A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in HypertensionNavjot Kaur0Ravinder Garg1Jasleen Kaur2Kamal Preet Palta3Mala Chandra4Shaminder Kaur5Ranabir Pal6Postgraduate Resident, Department of Pharmacology, GGS Medical College, Faridkot, Punjab, India.Professor and Head, Department of Medicine, GGS Medical College, Faridkot, Punjab, India.Professor and Head, Department of Pharmacology, GGS Medical College and Hospital, Faridkot, Punjab, India.Associate Consultant, Department of Emergency Medicine, Max Smart Hospital, Delhi, India.Postgraduate Resident, Department of Pharmacology, GGS Medical College and Hospital, Faridkot, Punjab, India.Associate Professor, Department of Medicine, GGS Medical College and Hospital, Faridkot, Punjab, India.Professor and Head, Department of Community Medicine, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, Andaman and Nicobar Islands, India.Introduction: A Fixed-Dose Combination (FDC) of antihypertensive agents of different groups might offer advantages of efficacy, tolerability and compliance over monotherapy. Aim: To compare efficacy and tolerability of ramipril/torsemide FDC with ramipril monotherapy. Materials and Methods: This prospective open labeled randomized comparative study was conducted on newly diagnosed 100 patients, suffering from primary hypertension. They were divided in two groups viz., Group A (Ramipril 5 mg/day) and Group B (Ramipril 5 mg with Torsemide 5 mg/day). The study drugs were prescribed for a period of 12 weeks. To find comparative efficacy, the primary goal BP was set at less than 140 mmHg systolic and 90 mmHg diastolic blood pressure. Haematological and biochemical assessments were embedded in the methods at baseline and at the end of study. All the participants were evaluated for dyselectrolytemia, Blood urea, Serum Creatinine, and lipid profile during the study period at baseline and three follow ups at 4th, 8th and 12th weeks along with recording of adverse drug reactions. To assess tolerability of both regimens, the participants were interviewed followed by physical examination and laboratory investigation. Results: The participants on FDC therapy (ramipril and torsemide) had shown significant reduction in ambulatory and office-measure BP compared to the participants on monotherapy (ramipril) with Stage I and Stage II hypertension. The goal BP was achieved with combination therapy in 4 weeks compared to monotherapy that was achieved in eight weeks. In the safety profiles, mild adverse drug reactions were reported with both the therapies. Conclusion: FDC treatment showed significant fall in systolic BP after 4 weeks and diastolic BP after 12 weeks compared to the monotherapy while both the regimens were well tolerated.https://jcdr.net/articles/PDF/10819/24715_150917_24715_CE[Ra]_F(Sh)_PF1(AA_GG)_PFA(NC_MJ_SS).pdfangiotensin converting enzymedyselectrolytemiafixed-dose combination |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Navjot Kaur Ravinder Garg Jasleen Kaur Kamal Preet Palta Mala Chandra Shaminder Kaur Ranabir Pal |
spellingShingle |
Navjot Kaur Ravinder Garg Jasleen Kaur Kamal Preet Palta Mala Chandra Shaminder Kaur Ranabir Pal A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension Journal of Clinical and Diagnostic Research angiotensin converting enzyme dyselectrolytemia fixed-dose combination |
author_facet |
Navjot Kaur Ravinder Garg Jasleen Kaur Kamal Preet Palta Mala Chandra Shaminder Kaur Ranabir Pal |
author_sort |
Navjot Kaur |
title |
A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension |
title_short |
A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension |
title_full |
A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension |
title_fullStr |
A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension |
title_full_unstemmed |
A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension |
title_sort |
comparative evaluation of ramipril as monotherapy and combination of ramipril with torsemide in hypertension |
publisher |
JCDR Research and Publications Private Limited |
series |
Journal of Clinical and Diagnostic Research |
issn |
2249-782X 0973-709X |
publishDate |
2017-11-01 |
description |
Introduction: A Fixed-Dose Combination (FDC) of antihypertensive
agents of different groups might offer advantages of efficacy,
tolerability and compliance over monotherapy.
Aim: To compare efficacy and tolerability of ramipril/torsemide
FDC with ramipril monotherapy.
Materials and Methods: This prospective open labeled
randomized comparative study was conducted on newly
diagnosed 100 patients, suffering from primary hypertension.
They were divided in two groups viz., Group A (Ramipril
5 mg/day) and Group B (Ramipril 5 mg with Torsemide 5
mg/day). The study drugs were prescribed for a period of
12 weeks. To find comparative efficacy, the primary goal
BP was set at less than 140 mmHg systolic and 90 mmHg
diastolic blood pressure. Haematological and biochemical
assessments were embedded in the methods at baseline
and at the end of study. All the participants were evaluated
for dyselectrolytemia, Blood urea, Serum Creatinine, and
lipid profile during the study period at baseline and three
follow ups at 4th, 8th and 12th weeks along with recording
of adverse drug reactions. To assess tolerability of both
regimens, the participants were interviewed followed by
physical examination and laboratory investigation.
Results: The participants on FDC therapy (ramipril and
torsemide) had shown significant reduction in ambulatory
and office-measure BP compared to the participants on
monotherapy (ramipril) with Stage I and Stage II hypertension.
The goal BP was achieved with combination therapy in 4
weeks compared to monotherapy that was achieved in eight
weeks. In the safety profiles, mild adverse drug reactions
were reported with both the therapies.
Conclusion: FDC treatment showed significant fall in systolic
BP after 4 weeks and diastolic BP after 12 weeks compared to
the monotherapy while both the regimens were well tolerated. |
topic |
angiotensin converting enzyme dyselectrolytemia fixed-dose combination |
url |
https://jcdr.net/articles/PDF/10819/24715_150917_24715_CE[Ra]_F(Sh)_PF1(AA_GG)_PFA(NC_MJ_SS).pdf |
work_keys_str_mv |
AT navjotkaur acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT ravindergarg acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT jasleenkaur acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT kamalpreetpalta acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT malachandra acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT shaminderkaur acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT ranabirpal acomparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT navjotkaur comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT ravindergarg comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT jasleenkaur comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT kamalpreetpalta comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT malachandra comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT shaminderkaur comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension AT ranabirpal comparativeevaluationoframiprilasmonotherapyandcombinationoframiprilwithtorsemideinhypertension |
_version_ |
1724591502737276928 |